Aelis Farma: second favorable opinion to continue the AEF0217 trial in Down syndrome
The independent Data Monitoring Committee (IDMC) has recommended that the Phase 2b trial of AEF0217 in Down syndrome continue without modification. This recommendation is based on a blinded interim analysis of safety data from 74 participants.
According to the press release published on November 16, 2026, the committee also issued a favorable opinion on the possible initiation of a 12-month open-label extension study.
No serious adverse events, two mild effects potentially related to the product
This second review expands on the first one, announced in July 2026. The latter covered 42 participants, 32 of whom had completed four weeks of treatment. The new analysis includes 54 participants who received at least 12 weeks of treatment.
At the data cutoff on September 14, 2026, 23 participants (31.1%) had reported a total of 42 treatment-emergent adverse events. All were of mild intensity, with the exception of one transient vasovagal episode of moderate intensity, judged by the investigator to be unrelated to the product.
Only two events, vomiting and acne, were assessed as potentially related to the treatment. No serious or severe adverse events were reported, nor any treatment discontinuation due to an adverse event.
Laboratory tests, electrocardiograms, and vital signs revealed no signal related to the treatment. Among the 14 adolescents aged 16 and 17, the proportion of affected participants (28.6%) is comparable to that of adults (31.7%).
As the analysis was conducted in a blinded manner, these data do not distinguish participants receiving placebo from those receiving one of the three doses of AEF0217 (0.1, 0.2, or 0.6 mg).
An extension study under consideration, results expected by the end of 2027
The IDMC's opinion also covers a one-year open-label extension study, which could follow the Phase 2b trial while maintaining independent safety monitoring. According to the company, it would accelerate the collection of the long-term tolerability data required for marketing authorization applications.
As of November 4, 2026, 108 participants had been randomized out of the 188 planned in France, Spain, and Italy. Of these, 38 had completed the 24 weeks of treatment.
Clinical data, intended to confirm the efficacy observed in Phase 1/2, are expected by the end of 2027, in line with the previously announced timeline.
Pier Vincenzo Piazza, Chief Executive Officer, linked this assessment to the retrospective study recently published by the group. According to him, this study suggests that the benefits previously observed “translate into significant improvements in daily life”.
The coordinating investigator, Prof. Rafael de la Torre Fornell, for his part awaits the completion of the trial “in order to determine whether the encouraging results previously observed with AEF0217 can be confirmed in this broader population”.